Extended Data Fig. 7: Memory phenotypes in CoV2-Dex+ and CoV2-Pent+ cells.
From: Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
a, b, Gating strategy for identifying naïve, stem cell memory (TSCM), central memory (TCM), effector/effector memory (Teffector/TEM), and effector memory T cells re-expressing CD45RA (TEMRA) in (a) CoV2-Dex– and CoV2-Dex+ cells or (b) CoV2-Pent– and CoV2-Pent+ cells. c, Percentages of naïve, TCM, Teffector/TEM, and TEMRA cells among CoV2-Pent– (gray) and CoV2-Pent+ (red) cells (n = 7). d, e, Percentages of naïve, TCM, Teffector/TEM, and TEMRA cells among CoV2-Dex– (gray) and CoV2-Dex+ (red) cells (d) six months and (e) one year after infection (n = 24 six months, n = 29 one year). f–h, Percentages of naïve, TSCM, TCM, Teffector/TEM, and TEMRA in CoV2-Dex+ cells in patients with HLA-A*01:01 versus HLA-A*11:01 allele (f) during acute infection, (g) six months and (h) one year after infection (acute: n = 22 HLA-A*01:01 and n = 6 HLA-A*11:01; six months: n = 19 HLA-A*01:01 and n = 5 HLA-A*11:01; one year: n = 20 HLA-A*01:01 and n = 9 HLA-A*11:01). i–k, Percentages of naïve, TSCM, TCM, Teffector/TEM, and TEMRA in CoV2-Dex+ cells in patients with mild versus severe disease (i) during acute infection, (j) six months and (k) one year after infection (acute: n = 16 mild, n = 12 severe; six months: n = 11 mild, n = 16 severe; one year: n = 19 mild, n = 10 severe). P-values were calculated with a Wilcoxon signed-rank test in c–e and with a Mann-Whitney-Wilcoxon test in f–k. All tests were performed two-sided.
